Glauconix Biosciences, Inc.
Karen Y. Torrejon has a strong background in biosciences and research. Karen Y. co-founded Humonix Biosciences, Inc. in 2014, where they currently serve as the Co-Founder and CSO. Karen Y. also founded Glauconix Biosciences, Inc. in 2019 and held the position of Founder and CSO until 2023. Prior to these entrepreneurial ventures, Karen worked at the College of Nanoscale Science and Engineering as a Graduate Research Assistant from 2010 to 2015. Karen Y. also has experience as a Research Associate at the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, where they conducted drug discovery and preclinical testing using novel chitosan nanoparticles.
Karen Y. Torrejon completed their education at the University at Albany, SUNY. Karen Y. earned a Bachelor's Degree in Chemistry and Physics, which they pursued from 2006 to 2010. Following that, they furthered their studies at the same institution and obtained a Doctor of Philosophy (Ph.D.) degree in Nanotechnology with a specialization in tissue engineering. This degree was completed between the years 2010 and 2015.
This person is not in any teams
Glauconix Biosciences, Inc.
www.glauconix-biosciences.com Glauconix Biosciences is a specialty pharma research company that uses an innovative platform technology to reduce the cost of ophthalmic drug development. Glauconix operates out of its laboratories located at the SUNY Polytechnic Institute-Albany, NY campus. We collaborate with academic and industry partners to help screen, identify and validate the unique MOA of the most effective drug candidates. Glauconix’s 3D tissue system can reduce the risk of clinical trial failure; saving time, labor and development costs. Early identification and validation of effective compounds or biologics, allows partners to confidently enter clinical trial.